SG11201808426XA - Compositions for treatment of wet age-related macular degeneration - Google Patents

Compositions for treatment of wet age-related macular degeneration

Info

Publication number
SG11201808426XA
SG11201808426XA SG11201808426XA SG11201808426XA SG11201808426XA SG 11201808426X A SG11201808426X A SG 11201808426XA SG 11201808426X A SG11201808426X A SG 11201808426XA SG 11201808426X A SG11201808426X A SG 11201808426XA SG 11201808426X A SG11201808426X A SG 11201808426XA
Authority
SG
Singapore
Prior art keywords
international
avegf
philadelphia
pct
treatment
Prior art date
Application number
SG11201808426XA
Inventor
Anna Tretiakova
James Wilson
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of SG11201808426XA publication Critical patent/SG11201808426XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization IIIM141101110101011111 HO 11111011101 111011011111100111011111011011# International Bureau 0.. .... .. ..... ..or::,„,' (10) International Publication Number (43) International Publication Date WO 2017/180936 Al 19 October 2017(19.10.2017) WIPO I PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 48/00 (2006.01) C07K 16/22 (2006.01) kind of national protection available): AE, AG, AL, AM, C12N 15/86 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (21) International Application Number: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2017/027529 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (22) International Filing Date: KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, 14 April 2017 (14.04.2017) MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (25) Filing Language: English RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (26) Publication Language: English TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 62/323,184 15 April 2016 (15.04.2016) US (84) Designated States (unless otherwise indicated, for every 62/331,100 3 May 2016 (03.05.2016) US kind of regional protection available): ARIPO (BW, GH, 62/442,946 5 January 2017 (05.01.2017) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/460,515 17 February 2017 (17.02.2017) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, 62/466,721 3 March 2017 (03.03.2017) US TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (71) Applicant: THE TRUSTEES OF THE UNIVERSITY LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, OF PENNSYLVANIA [US/US]; 3160 Chestnut Street, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, Suite 200, Philadelphia, PA 19104 (US). GW, KM, ML, MR, NE, SN, TD, TG). (72) Inventors: TRETIAKOVA, Anna, P.; 2531 Parrish Published: Street, Philadelphia, PA 19103 (US). WILSON, James, — M.; 1831 Delancey Street, Philadelphia, PA 19103 (US). with international search report (Art. 21(3)) — before the expiration of the time limit for amending the (74) Agents: KODROFF, Cathy, A. et al.; Howson & Howson claims and to be republished in the event of receipt of LLP, 350 Sentry Parkway, Building 620, Suite 210, Blue amendments (Rule 48.2(h)) Bell, PA 19422 (US). — with sequence listing part of description (Rule 5.2(a)) (54) Title: COMPOSITIONS FOR TREATMENT OF WET AGE-RELATED MACULAR DEGENERATION Rabbitpalobin CEP Mum% On 422A paVA i signal L - \ , ..'k 14 chain 1-1 a M 01 0 GC 1-1 L .. ' (57) : A recombinant adeno-associated :::;) provided herein. The rAAV comprises N elements which direct expression of 0 (aVEGF), a coding sequence for aVEGF, pression of the anti -VEGF Fab in the eye. Also provided herein are liquid suspensions containing these rAAV8.aVEGF and meth- ods of using same for treatment of wet AMD and other ocular conditions. a FIG 1 virus (rAAV) having an AAV8 capsid which is suitable for intra-retinal injection is a vector genome packaged within the capsid which contains, operably linked to regulatory anti- human vascular endothelial growth factor (VEGF) antigen binding antibody fragment wherein the coding sequence is operably linked to regulatory elements which direct ex -
SG11201808426XA 2016-04-15 2017-04-14 Compositions for treatment of wet age-related macular degeneration SG11201808426XA (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662323184P 2016-04-15 2016-04-15
US201662331100P 2016-05-03 2016-05-03
US201762442946P 2017-01-05 2017-01-05
US201762460515P 2017-02-17 2017-02-17
US201762466721P 2017-03-03 2017-03-03
PCT/US2017/027529 WO2017180936A1 (en) 2016-04-15 2017-04-14 Compositions for treatment of wet age-related macular degeneration

Publications (1)

Publication Number Publication Date
SG11201808426XA true SG11201808426XA (en) 2018-10-30

Family

ID=59253994

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201808426XA SG11201808426XA (en) 2016-04-15 2017-04-14 Compositions for treatment of wet age-related macular degeneration
SG10201913159UA SG10201913159UA (en) 2016-04-15 2017-04-15 Compositions for treatment of wet age-related macular degeneration

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201913159UA SG10201913159UA (en) 2016-04-15 2017-04-15 Compositions for treatment of wet age-related macular degeneration

Country Status (10)

Country Link
US (2) US11197937B2 (en)
EP (1) EP3452103A1 (en)
JP (3) JP7046828B2 (en)
KR (2) KR20230130765A (en)
AU (1) AU2017248731A1 (en)
CA (1) CA3019426A1 (en)
IL (1) IL262207A (en)
MA (1) MA44873A (en)
SG (2) SG11201808426XA (en)
WO (1) WO2017180936A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
SG11201805420SA (en) 2015-12-30 2018-07-30 Kodiak Sciences Inc Antibodies and conjugates thereof
EP3697449A1 (en) * 2017-10-18 2020-08-26 REGENXBIO Inc. Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified vegf-trap
EP4219695A3 (en) * 2017-11-27 2024-01-17 4D Molecular Therapeutics Inc. Adeno-associated virus variant capsids and use for inhibiting angiogenesis
EP3727468A4 (en) * 2017-12-19 2021-09-22 Akouos, Inc. Aav-mediated delivery of therapeutic antibodies to the inner ear
US20210093734A1 (en) * 2018-02-20 2021-04-01 The Trustees Of The University Of Pennsylvania Compositions for treatment of wet age-realted macular degeneration
JP2022049718A (en) * 2019-02-05 2022-03-30 アステラス製薬株式会社 Treatment of retinal degenerative disease by introduction of cx3cl1 gene using adeno-associated virus
SG11202110789VA (en) 2019-04-03 2021-10-28 Regenxbio Inc Gene therapy for eye pathologies
KR20220051246A (en) 2019-08-26 2022-04-26 리젠엑스바이오 인크. Treatment of diabetic retinopathy with fully human post-translational modified anti-VEGF Fab
CN114728049A (en) 2019-10-07 2022-07-08 再生生物股份有限公司 Adeno-associated virus vector pharmaceutical compositions and methods
CN114786731A (en) 2019-10-10 2022-07-22 科达制药股份有限公司 Methods of treating ocular disorders
US20230183741A1 (en) * 2020-05-11 2023-06-15 University Of Florida Research Foundation, Incorporated Disease correction by delivery of aav8 vectors expressing codon optimized naglu
WO2021255589A1 (en) * 2020-06-16 2021-12-23 Intas Pharmaceuticals Ltd. An anti-vegf scfab adeno-associated virus (aav) vector and uses thereof
WO2021255590A1 (en) * 2020-06-16 2021-12-23 Intas Pharmaceuticals Ltd. An anti-vegf scfv adeno-associated virus (aav) vector and uses thereof
IL298527A (en) * 2020-10-16 2023-01-01 Gyroscope Therapeutics Ltd Nucleic acid encoding an anti-vegf entity and a negative complement regulator and uses thereof for the treatment of age-related macular degeneration
AU2021391433A1 (en) * 2020-12-01 2023-06-22 Akouos, Inc. Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms
CA3209779A1 (en) 2021-02-01 2022-08-04 Regenxbio Inc. Gene therapy for neuronal ceroid lipofuscinoses
AR128422A1 (en) * 2022-02-02 2024-05-08 Akouos Inc ANTI-VEGF ANTIBODY CONSTRUCTIONS AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SCHWANNOMA
WO2023196873A1 (en) 2022-04-06 2023-10-12 Regenxbio Inc. Pharmaceutical composition comprising a recombinant adeno-associated virus vector with an expression cassette encoding a transgene forsuprachoidal administration
WO2024073669A1 (en) 2022-09-30 2024-04-04 Regenxbio Inc. Treatment of ocular diseases with recombinant viral vectors encoding anti-vegf fab

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3824633B2 (en) 1993-02-12 2006-09-20 ザ・ボード・オブ・トラスティーズ・オブ・ザ・リランド・スタンフォード・ジュニアー・ユニバーシティ Regulatory transcription of target genes and other biological consequences
EP0805819B1 (en) 1994-12-29 2012-02-08 Massachusetts Institute Of Technology Chimeric dna-binding proteins
CA2219080A1 (en) 1995-06-07 1996-12-27 Ariad Gene Therapeutics, Inc. Rapamycin-based regulation of biological events
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
JP2003524368A (en) 1997-08-26 2003-08-19 アリアド ジーン セラピューティクス インコーポレイテッド Fusion protein comprising a dimerization domain, a trimerization domain or a tetramerization domain and a complementary heterologous transcriptional activation domain, a transcription repression domain, a DNA binding domain or a ligand binding domain
AU752129B2 (en) 1997-08-27 2002-09-05 Ariad Gene Therapeutics, Inc. Chimeric transcriptional activators and compositions and uses related thereto
WO1999036553A2 (en) 1998-01-15 1999-07-22 Ariad Gene Therapeutics, Inc. Regulation of biological events using multimeric chimeric proteins
AU766513B2 (en) 1998-02-13 2003-10-16 Board Of Trustees Of The Leland Stanford Junior University Novel dimerizing agents, their production and use
JP4827353B2 (en) 1999-08-09 2011-11-30 ターゲティッド ジェネティクス コーポレイション Increased expression of single-stranded heterologous nucleotide sequences from recombinant viral vectors by designing sequences to form intrastrand base pairs
US7067526B1 (en) 1999-08-24 2006-06-27 Ariad Gene Therapeutics, Inc. 28-epirapalogs
WO2001029242A2 (en) 1999-10-21 2001-04-26 Monsanto Company Post-translational modification of recombinant proteins produced in plants
GB2362884A (en) 2000-05-30 2001-12-05 Isis Innovation Extended duration of airway gene therapy
WO2002007514A2 (en) 2000-07-26 2002-01-31 Ludwig Institute Of Cancer Research Glycosylated vegf-b and method for increasing the amount of soluble vegf-b
NZ600121A (en) 2001-11-13 2013-12-20 Univ Pennsylvania A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
AU2002360291A1 (en) 2001-12-17 2003-06-30 The Trustees Of The University Of Pennsylvania Adeno-associated virus (aav) serotype 8 sequences
CA2472922A1 (en) 2002-02-11 2003-08-21 Genentech, Inc. Antibody variants with faster antigen association rates
US20040208847A1 (en) 2003-03-28 2004-10-21 Fabienne Rolling Method and vectors for selectively transducing retinal pigment epithelium cells
JP5054975B2 (en) 2003-09-30 2012-10-24 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Syngeneic strains of adeno-associated virus (AAV), sequences, vectors containing them and uses thereof
JP5702519B2 (en) 2005-04-07 2015-04-15 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア How to increase the function of an AAV vector
JP4495210B2 (en) 2005-06-09 2010-06-30 パナソニック株式会社 Amplitude error compensator and orthogonality error compensator
ES2666170T3 (en) 2007-10-30 2018-05-03 Genentech, Inc. Purification of antibodies by cation exchange chromatography
AR069501A1 (en) 2007-11-30 2010-01-27 Genentech Inc ANTI-VEGF ANTIBODIES (VASCULAR ENDOTELIAL GROWTH FACTOR)
KR101010352B1 (en) 2008-05-30 2011-01-25 삼성중공업 주식회사 Apparatus and Method of Power Control
DK2356270T3 (en) 2008-11-07 2016-12-12 Fabrus Llc Combinatorial antibody libraries and uses thereof
WO2010138263A2 (en) 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof
SG177265A1 (en) 2009-06-17 2012-02-28 Abbott Biotherapeutics Corp Anti-vegf antibodies and their uses
US8927514B2 (en) 2010-04-30 2015-01-06 City Of Hope Recombinant adeno-associated vectors for targeted treatment
US8628966B2 (en) 2010-04-30 2014-01-14 City Of Hope CD34-derived recombinant adeno-associated vectors for stem cell transduction and systemic therapeutic gene transfer
US8663624B2 (en) * 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
WO2012057363A1 (en) 2010-10-27 2012-05-03 学校法人自治医科大学 Adeno-associated virus virions for transferring genes into neural cells
CA2826273C (en) 2011-02-10 2021-11-02 The University Of North Carolina At Chapel Hill Viral vectors with modified transduction profiles and methods of making and using the same
EP2678433B1 (en) * 2011-02-22 2017-05-03 California Institute of Technology Delivery of proteins using adeno-associated virus (aav) vectors
RS60207B1 (en) 2011-04-22 2020-06-30 Univ California Adeno-associated virus virions with variant capsid and methods of use thereof
EP2559443A1 (en) 2011-08-16 2013-02-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of an ocular disease in a subject
US9169299B2 (en) 2011-08-24 2015-10-27 The Board Of Trustees Of The Leleand Stanford Junior University AAV capsid proteins for nucleic acid transfer
US20130090375A1 (en) * 2011-10-06 2013-04-11 Cornell University Virus-mediated delivery of bevacizumab for therapeutic applications
US9677088B2 (en) 2012-05-09 2017-06-13 Oregon Health & Science University Adeno associated virus plasmids and vectors
TWI775096B (en) 2012-05-15 2022-08-21 澳大利亞商艾佛蘭屈澳洲私營有限公司 Treatment of amd using aav sflt-1
CN104884049A (en) 2012-11-08 2015-09-02 克莱尔塞德生物医学股份有限公司 Methods and devices for the treatment of ocular diseases in human subjects
EP2954051B1 (en) 2013-02-08 2019-03-27 The Trustees Of The University Of Pennsylvania Modified aav8 capsid for gene transfer for retinal therapies
WO2014160092A1 (en) 2013-03-13 2014-10-02 The Children's Hospital Of Philadelphia Adeno-associated virus vectors and methods of use thereof
KR102346455B1 (en) 2013-03-15 2022-01-04 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Compositions and methods for treating mpsi
EP3561062A1 (en) 2013-09-13 2019-10-30 California Institute of Technology Selective recovery
CN106232618A (en) 2013-10-11 2016-12-14 马萨诸塞眼科耳科诊所 Method of prediction ancestors' virus sequence and application thereof
PT3077519T (en) 2013-12-03 2021-05-13 Hookipa Biotech Ag Cmv vaccines
GB201403684D0 (en) 2014-03-03 2014-04-16 King S College London Vector
US10746742B2 (en) 2014-04-25 2020-08-18 Oregon Health & Science University Methods of viral neutralizing antibody epitope mapping
EP3919508A1 (en) * 2014-04-25 2021-12-08 The Trustees of The University of Pennsylvania Ldlr variants and their use in compositions for reducing cholesterol levels
CN106470736B (en) 2014-05-13 2021-05-28 宾夕法尼亚州大学信托人 Compositions comprising AAV expressing diabody constructs and uses thereof
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
US9840553B2 (en) * 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US10064752B2 (en) 2014-09-11 2018-09-04 Orbit Biomedical Limited Motorized suprachoroidal injection of therapeutic agent
AU2016219789B2 (en) 2015-02-20 2021-03-25 Fondazione Telethon Methods and compositions for treating genetic eye diseases
WO2016200543A2 (en) * 2015-05-13 2016-12-15 The Trustees Of The University Of Pennsylvania Aav-mediated expression of anti-inluenza antibodies and methods of use thereof
JP2018526003A (en) * 2015-08-31 2018-09-13 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Chimeric AAV-anti-VEGF for treating canine cancer
GB201519086D0 (en) 2015-10-28 2015-12-09 Syncona Partners Llp Gene Therapy
BR112018013805A2 (en) 2016-01-08 2018-12-11 Clearside Biomedical, Inc. methods and devices for the treatment of aflibercept posterior eye disorder and other biological products
WO2017181021A1 (en) 2016-04-15 2017-10-19 Regenxbio Inc. Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab
CA3076905A1 (en) 2017-09-27 2019-04-04 The Johns Hopkins University Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab
SG11202110789VA (en) 2019-04-03 2021-10-28 Regenxbio Inc Gene therapy for eye pathologies

Also Published As

Publication number Publication date
US20190381194A1 (en) 2019-12-19
JP7046828B2 (en) 2022-04-04
MA44873A (en) 2019-03-13
JP2022084809A (en) 2022-06-07
WO2017180936A1 (en) 2017-10-19
KR20190031196A (en) 2019-03-25
CA3019426A1 (en) 2017-10-19
EP3452103A1 (en) 2019-03-13
JP7492556B2 (en) 2024-05-29
US11197937B2 (en) 2021-12-14
AU2017248731A1 (en) 2018-10-18
JP2019518427A (en) 2019-07-04
IL262207A (en) 2018-11-29
NZ746729A (en) 2023-08-25
JP7111924B2 (en) 2022-08-02
KR102574810B1 (en) 2023-09-08
JP2022141856A (en) 2022-09-29
KR20230130765A (en) 2023-09-12
SG10201913159UA (en) 2020-02-27
US20220288238A1 (en) 2022-09-15

Similar Documents

Publication Publication Date Title
SG11201808426XA (en) Compositions for treatment of wet age-related macular degeneration
SG11201907714UA (en) Adeno-associated virus (aav) clade f vector and uses therefor
SG11201808812RA (en) Novel aav8 mutant capsids and compositions containing same
SG11201807188VA (en) Modified cells for immunotherapy
SG11201808422QA (en) Gene therapy for treating hemophilia a
SG11201909949XA (en) Targeted immunotolerance
SG11201804713VA (en) TARGETING PEPTIDES FOR DIRECTING ADENO-ASSOCIATED VIRUSES (AAVs)
SG11201908280SA (en) "chimeric molecules and uses thereof"
SG11201909572QA (en) Methods for the treatment of subjects having a hepatitis b virus (hbv) infection
SG11201811432WA (en) Rna for cancer therapy
SG11201809684YA (en) Adeno-associated virus variant capsids and methods of use thereof
SG11201810697QA (en) Chimeric antigen receptor and car-t cells that bind bcma
SG11201906392WA (en) Nucleoside-modified rna for inducing an immune response against zika virus
SG11201903454VA (en) Immunologically discernible cell surface variants for use in cell therapy
SG11201909941QA (en) Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
SG11201803956UA (en) Anti-dr5 antibodies and methods of use thereof
SG11201908391XA (en) Methods for modulating an immune response
SG11201804400SA (en) Scalable methods for producing recombinant adeno-associated viral (aav) vector in serum-free suspension cell culture system suitable for clinical use
SG11201807279QA (en) Binding proteins and methods of use thereof
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201811363YA (en) Anti-zika virus antibodies and methods of use
SG11201909499QA (en) Humanized antigen-binding domains against cd19 and methods of use
SG11201906192SA (en) Methods of treating cancer with anti-pd-1 antibodies
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201810048VA (en) Tri-segmented pichinde viruses as vaccine vectors